Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Published:2024-07 Issue:7 Volume:35 Page:643-655
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ambrosini M.^ORCID,Rousseau B.,Manca P.^ORCID,Artz O.^ORCID,Marabelle A.,André T.^ORCID,Maddalena G.,Mazzoli G.,Intini R.,Cohen R.^ORCID,Cercek A.,Segal N.H.,Saltz L.,Varghese A.M.,Yaeger R.,Nusrat M.^ORCID,Goldberg Z.,Ku G.Y.^ORCID,El Dika I.,Margalit O.,Grinshpun A.,Kasi P.M.,Schilsky R.^ORCID,Lutfi A.^ORCID,Shacham-Shmueli E.,Khan Afghan M.,Weiss L.,Westphalen C.B.^ORCID,Conca V.^ORCID,Decker B.^ORCID,Randon G.,Elez E.^ORCID,Fakih M.,Schrock A.B.,Cremolini C.,Jayachandran P.,Overman M.J.,Lonardi S.,Pietrantonio F.^ORCID

Publisher

Elsevier BV

Reference48 articles.

1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade;Le;Science (New York, N.Y.),2017

2. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer;Overman;J Clin Oncol,2018

3. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study;Overman;Lancet Oncol,2017

4. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164;Le;J Clin Oncol,2019

5. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer;André;N Engl J Med,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy;Molecular Cancer;2024-09-02

2. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?;Current Oncology Reports;2024-07-30

3. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer;Annals of Oncology;2024-07